+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Characteristics of Dopaminergic Neurons in the Aged Male Rat

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Male rats were sacrificed at 5 months (young rats) or at 24 months (aged rats). When compared with values in young rats, aged rats had higher serum concentrations of prolactin and lower concentrations of luteinizing hormone and testosterone. In the median eminence, which contains the terminals of tuberoinfundibular dopamine (DA) neurons, the concentrations of DA and dihydroxyphenylacetic acid (DOPAC), and the rate of DA synthesis (accumulation of DOPA after the inhibition of DOPA decarboxylase) were decreased in aged rats. In the striatum, which contains the terminals of nigrostriatal DA neurons, the concentration of DA was reduced, but this change was not accompanied by a decrease in DOPAC concentrations or DOPA accumulation. The decreased DA concentration observed in the median eminence and striatum of aged rats may reflect the loss of DA neurons. An attempt was made to mimic the age-related loss of nigrostriatal and tuberoinfundibular DA neurons by pretreating rats with intraventricular injections of 6-hydroxydopamine. In these animals the decrease of DA in the median eminence was accompanied by a concomitant reduction in the rate of DOPA accumulation, whereas in the striatum the concentration of DA was reduced, but DOPA accumulation remained normal. These results suggest that in aged and 6-hydroxydopamine-treated rats, the loss of nigrostriatal DA neurons is accommodated for by a compensatory increase in the activity of the remaining neurons whereas tuberoinfundibular DA neurons are unable to compensate in a similar manner.

          Related collections

          Author and article information

          S. Karger AG
          26 March 2008
          : 31
          : 3
          : 222-227
          Department of Pharmacology and Toxicology and Department of Physiology, Michigan State University, East Lansing, Mich.
          123078 Neuroendocrinology 1980;31:222–227
          © 1980 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Original Paper


          Comment on this article